Goldman Sachs lifts Allianz SE to “buy,” sees 16% upside on strong EPS outlook

Goldman Sachs upgraded Allianz to buy from neutral and lifted its 12-month target to €450 from €410, implying 15.6% upside. Allianz reported 2025 core operating EPS growth of 12.5%, €8.6B in net cash remittances, an 18.1% core ROE, and a 218% Solvency II ratio, while Goldman’s 2026-2028 EPS estimates run from €29.97 to €37.21. The note highlights strong P&C profitability, manageable private credit exposure, and potential AI-driven productivity gains, supporting a constructive medium-term view.

Analysis

The market is likely underpricing how much of Allianz’s re-rating is self-funding: stronger capital generation plus a large remittance profile reduces the probability that valuation is constrained by the usual European insurer overhang of trapped capital. That matters because in insurance, a higher multiple rarely comes from earnings alone; it usually comes when investors start believing excess capital can be returned through cycles without forcing de-risking. The cleaner takeaway is that the business mix is becoming more resilient exactly where the market still discounts cyclicality — P&C underwriting and capital-light fee-like economics are doing more of the heavy lifting than headline earnings suggest.

The bigger second-order implication is competitive. If Allianz is sustaining high-teens ROE while also investing aggressively in technology, peers with weaker scale or thinner balance sheets may face an unpleasant choice between spending to keep up or defending margins. That can show up first in lower-quality players via worse combined ratios and less pricing discipline, especially if AI-driven productivity improvements reduce expense drag faster than anticipated. In other words, the winner may be the insurer that can turn tech spend into underwriting discipline rather than just customer acquisition.

The main risk is that the market extrapolates current resilience too far into a benign loss environment. Private credit exposure is not the core issue; the real tail risk is correlated stress across credit, claims inflation, and capital markets all at once, which would pressure both earnings and the solvency surplus that supports buybacks/remittances. Time horizon matters: near term the stock can keep grinding higher on upgraded estimates, but over 12-24 months the entry point will depend on whether management proves it can keep ROE elevated without sacrificing reserve quality or balance-sheet flexibility.

Key Decisions for Investors

• Long ALVG/Allianz common equity on a 3-6 month horizon; add on pullbacks rather than chasing strength. Risk/reward is attractive if the market continues to re-rate the stock toward book-value multiple expansion, but trim if the solvency narrative weakens or combined ratio trends back above the low-90s.
• Pair trade: long ALVG vs short a lower-quality European P&C composite or insurer with weaker capital returns. The thesis is that capital-light earnings plus remittances should compress the valuation gap over the next 2-4 quarters as investors favor balance-sheet quality over headline growth.
• Buy medium-dated call spreads on ALVG into any short-term consolidation. This expresses upside from continued estimate revisions and capital return optionality while limiting downside if broader financials de-rate on macro volatility.
• For a relative value basket, overweight insurers with strong solvency and technology scale, underweight lenders/asset managers exposed to private-credit beta. The market is likely to reward firms that can absorb AI capex and still return capital efficiently.
• Set a risk trigger around any material solvency ratio compression or adverse reserve commentary; if that emerges, reduce exposure quickly because the valuation support is mostly driven by perceived surplus durability rather than near-term EPS alone.